Bausch + Lomb Corporation (BLCO) Stock

Healthcare · Medical Instruments & Supplies · Member of Other US Stocks

Bausch + Lomb Corporation (BLCO) closed at USD 16.04 on 2026-10-14, a change of +5.5 % over the past year, with a market capitalization of USD 5.95B.

Bausch + Lomb Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bausch + Lomb Corporation key figures

Previous close

USD 16.04 (2026-10-14)

1-year change

+5.5 %

Market cap

USD 5.95B

Enterprise value

USD 10.77B

P/E ratio (trailing)

-32.04

P/E ratio (forward)

14.96

EPS (trailing)

-0.52

EPS (forward)

1.11

PEG ratio

0.89

Price to book

0.92

Revenue growth

9.1 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.12

Employees

13,000

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bausch + Lomb Corporation

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bausch + Lomb Corporation and compare it with other stocks.